Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Notes Payables (2016 - 2026)

Cryo Cell International's Notes Payables history spans 13 years, with the latest figure at $191085.0 for Q1 2026.

  • Quarterly results put Notes Payables at $191085.0 for Q1 2026, up 6.88% from a year ago — trailing twelve months through Feb 2026 was $191085.0 (up 6.88% YoY), and the annual figure for FY2025 was $183650.0, up 7.72%.
  • Notes Payables for Q1 2026 was $191085.0 at Cryo Cell International, up from $183650.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.1 million in Q1 2022 to a low of $150527.0 in Q4 2022.
  • The 5-year median for Notes Payables is $171605.0 (2024), against an average of $237229.5.
  • The sharpest move saw Notes Payables plummeted 94.21% in 2022, then grew 10.04% in 2023.
  • Year by year, Notes Payables stood at $150527.0 in 2022, then grew by 10.04% to $165641.0 in 2023, then increased by 2.93% to $170488.0 in 2024, then increased by 7.72% to $183650.0 in 2025, then increased by 4.05% to $191085.0 in 2026.
  • According to Business Quant data, Notes Payables over the past three periods came in at $191085.0, $183650.0, and $179187.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.